VERU-111 Promotes an Anti-Tumor Response Through Restoration of Gut Microbial Homeostasis and Associated Metabolic Dysregulation.

VERU-111 treatment increased alpha and beta diversity of gut microbial communities in AOM/DSS-induced CRC mice.

• Study used 16S rRNA gene amplicon sequencing of fecal samples from different experimental groups
• The murine model was azoxymethane (AOM) and dextran sodium sulfate (DSS)-induced colorectal cancer
• Increased alpha diversity indicates greater species richness and evenness within individual samples
• Increased beta diversity indicates greater differences in microbial community composition between groups

VERU-111 treatment significantly increased the relative abundance of several gut-protective bacterial species compared to DSS-alone treated mice.

• Increased bacterial species included Verrucomicrobiota species, Muribaculum intestinale, Alistipes finegoldii, Turicibacter, and Akkermansia muciniphila
• Akkermansia muciniphila is described as a 'well-known gut-protective bacterial species'
• Comparisons were made against mice treated with DSS alone
• These increases were characterized as significant relative abundance changes

VERU-111 administration diminished the relative abundance of Ruminococcus, which is negatively correlated with immune checkpoint blockade therapy.

• Ruminococcus abundance was reduced following VERU-111 treatment
• The paper notes that Ruminococcus is negatively correlated with immune checkpoint blockade therapy
• This reduction was identified through 16S rRNA gene amplicon sequencing analysis
• This finding suggests a potential interaction between VERU-111 treatment and immunotherapy responsiveness

KEGG pathway analysis predicted that the microbial shift after VERU-111 administration was associated with suppression of several metabolic and cancer-related pathways.

• Functional potential of microbial communities was predicted using Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis
• KEGG analysis was performed using 16S rRNA gene sequencing data as input
• The suppressed pathways included metabolic and cancer-related categories
• These pathway suppressions were suggested to at least in part facilitate suppression of CRC

Chemotherapy regimens are known to disrupt gut microbiota composition, but the effects of specific chemotherapeutic agents including VERU-111 have been insufficiently explored.

• Colorectal cancer is currently the third most common cancer worldwide
• Chemotherapy-induced microbiota disruption leads to long-term health consequences for cancer patients
• The study was specifically designed to assess changes in gut microbiota following VERU-111 treatment for CRC
• VERU-111 was studied as a chemotherapy agent in the context of CRC treatment